Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
